

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
09 December 2021 (09.12.2021)



(10) International Publication Number
WO 2021/247885 A3

(51) International Patent Classification:
C12N 15/113 (2010.01)

(21) International Application Number:
PCT/US2021/035730

(22) International Filing Date:
03 June 2021 (03.06.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/033,128 01 June 2020 (01.06.2020) US

(71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventors: LIN, Daniel C. H.; c/o Amgen Inc., One Amgen Center Drive, Law Department-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US). OLLMANN, Michael; c/o Amgen Inc., One Amgen Center Drive, Law Department-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US). MURRAY, Justin K.; c/o Amgen Inc., One Amgen Center Drive, Law Department-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US). HERBERICH, Bradley J.; c/o Amgen Inc., One Amgen Center Drive, Law Department-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US). DAS, Amrita; c/o Amgen Inc., One Amgen Center Drive, Law Department-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US). COLLINS, Patrick; c/o Amgen Inc., One Amgen Center Drive, Law Department-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US). HOMANN, Oliver; c/o Amgen Inc., One Amgen Center Drive, Law Department-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US).

(74) Agent: KONG, Lawrence B.; 1120 Veterans Blvd., South San Francisco, California 94080 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- the filing date of the international application is within two months from the date of expiration of the priority period (Rule 26bis.3)

(88) Date of publication of the international search report:
10 February 2022 (10.02.2022)

(54) Title: RNAI CONSTRUCTS FOR INHIBITING HSD17B13 EXPRESSION AND METHODS OF USE THEREOF

(57) Abstract: The present invention relates to RNAi constructs for reducing expression of the HSD17B13 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.

WO 2021/247885 A3